TAKE Limited Returns to Profitability: H1 FY27 Consolidated PAT ₹32.75 Million
TAKE Limited reported H1 FY27 consolidated PAT of ₹32.75 Million, returning to profitability from a loss in H1 FY26. Consolidated income was ₹615.54 Million. The company launched TAKE.Health and a ₹50 Million Innovation Fund.
The return to profitability after a period of losses is a major positive development. The strategic initiatives in digital health, AI, and longevity indicate significant future growth potential, impacting the company's valuation and investor confidence.
The company has returned to profitability on both consolidated and standalone bases, with significant year-on-year growth in PAT and QOQ growth in Q2. The launch of new initiatives like TAKE.Health and an Innovation Fund indicates a positive strategic direction.
TAKE Limited, a technology-driven company focused on healthcare and life sciences, has announced its financial results for the half year ended September 30, 2026. The company reported a consolidated Total Income of ₹615.54 Million (approximately ₹46.17 crore) and a consolidated Profit After Tax (PAT) of ₹32.75 Million (approximately ₹2.45 crore) for H1 FY27. This marks a significant turnaround from a loss of ₹2.13 Million (approximately ₹0.16 crore) in the corresponding period of the previous year.
On a standalone basis, the company recorded a Total Income of ₹280.52 Million (approximately ₹21.04 crore) and a Net Profit of ₹31.89 Million (approximately ₹2.39 crore) for the same period, compared to a loss of ₹7.83 Million (approximately ₹0.59 crore) in H1 FY26.
For the second quarter of FY27, consolidated Total Income stood at ₹298.52 Million (approximately ₹22.39 crore), with consolidated Net Profit increasing to ₹22.12 Million (approximately ₹1.66 crore), a 108.17% quarter-on-quarter growth. Standalone Net Profit for Q2 FY27 increased to ₹22.21 Million (approximately ₹1.66 crore), a 129.36% quarter-on-quarter growth.
In line with its strategic direction, TAKE Limited launched TAKE.Health, an intelligent digital health companion, and a ₹50 Million (approximately ₹3.75 crore) Innovation Fund with an initial corpus of ₹5 crore to support startups in AI, deep technology, and digital health. The company also announced its entry into India's longevity and anti-ageing market.
The company's strategic priorities include expanding TAKE.Health, developing longevity and wellness offerings, evaluating investment opportunities through its Innovation Fund, and exploring AI applications in healthcare. Management emphasizes execution, developing commercially sustainable offerings, and maintaining financial discipline.
What to do with a filing like this
TAKE Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TAKE Limited. Read the original for the full detail.